Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A press release issued by the University of Toronto on Monday may have given many people the idea that a “BlackBerry-sized” device carrying a microchip would shortly be available as a tool to diagnose prostate cancer in less than an hour — with the ability to differentiate between high- and low-risk forms of the disease.
Filed under: Diagnosis, Risk | Leave a Comment »
There have been several news reports about a survey conducted by Hoffman et al. and reported this week in the Archives of Internal Medicine. The survey suggests that the degree of communication about PSA testing between men and the doctors is generally poor.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, PSA, risk, testing | 1 Comment »
The Prostate Cancer Research Program (PCRP) of the Department of Defense’s Congressionally Directed Medical Research Program (DOD CDMRP) has just issued the first issue of a new newsletter called PCRP Perspectives, which discusses its activities and which is targeted primarily to interested consumer reviewers and scientist/grant applicants as well as those who sit on the [...]
Filed under: Uncategorized | Leave a Comment »
We apologize for a temporary news hiatus over the past few days. This has been a consequence of travel and work pressures. We hope to be able to return to “normal service” later today.
Filed under: Uncategorized | Comments Off
A new report is suggesting that the use of PSA and DRE testing in African Americans declined between 2002 and 2006.
Filed under: Diagnosis, Risk | Tagged: African American, risk | Leave a Comment »
Earlier this year we reported the initial results of a truly randomized Canadian trial of cryotherapy vs. external beam radiation therapy (EBRT) for the treatment of localized prostate cancer. The same group of authors have now reported follow-up data on quality of life.
Filed under: Management, Treatment | Tagged: cryoablation, cryotherapy, EBRT, external beam radiation therapy, randomized, trial | 2 Comments »
According to a media release issued yesterday by Dendreon, the company now expects to submit a revised New Drug Application for sipuleucel-T (Provenge) to the US Food and Drug Administration (FDA) in November this year.
Filed under: Drugs in development | Tagged: Provenge, sipuleucel-T | Leave a Comment »
According to a media release from Medivation, Inc. earlier today, the company has treated the first patient in a Phase III clinical trial of the novel androgen receptor antagonist MDV3100 in advanced prostate cancer.
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, MDV3100 | 2 Comments »
Today’s news reports cover items on: Extent and number of biopsy cores and eligibility for active surveillance Intermittent vs. complete androgen deprivation Hormone therapy and risk for cardiovascular disease and death Surrogate markets for disease progression in men with CRPC
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, androgen deprivation, biopsy, cardiovasular, castration-resistant prostate cancer, complete, CRPC, hormone therapy, intermittent, marker, protocol, side effects, surrogate | Leave a Comment »
Yesterday we reported a study suggesting the potential of hyalouronidase staining as a method to differentiate between aggressive and indolent prostate cancers at the time of diagnosis. Now a report in the British Journal of Cancer suggests that heat shock protein 27 (Hsp-27) may also have this potential.
Filed under: Diagnosis, Risk | Tagged: aggressive, heat shock protein, Hsp-27, risk | Leave a Comment »
A key goal of the prostate cancer research community has been the identification of markers that could help us to better identify patients at high risk for prostate cancer progression as early as possible in the disease process. It now appears that the presence of an enzyme called HYAL-1 hyaluronidase and hyaluronic acid staining in [...]
Filed under: Diagnosis, Risk | Tagged: HYAL-1, hyaluronic acid, hyaluronidase, prediction, risk, staining | Leave a Comment »
Jonathon Epstein, MD, at Johns Hopkins is widely considered to be one of the pre-eminent prostate cancer pathologists in the world today, so it is worth listening when he says that the Gleason grading system needs revision.
Filed under: Diagnosis, Management, Treatment | Tagged: Gleason, grade, outcome, revised, score | 4 Comments »
Traditionally, we have believed that a small but significant percentage of men with organ-confined, Gleason 6 prostate cancer would have biochemical progression after a radical prostatectomy. New data from Johns Hopkins suggest that such disease progression should be extremely rare.
Filed under: Management, Treatment | Tagged: Gleason 6, outcomes, radical prostatectomy | 4 Comments »
A new analysis of data from over 7,000 radical prostatectomy patients treated at major academic medical centers suggests that the prognostic value of the number, size, and placement of positive surgical margins is very limited.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: positive surgical margin, prognosis, progression | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site